Investing.com -- BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is being overtaken by rival Eli Lilly’s rapidly advancing pipeline.
The brokerage said Lilly’s progress with its oral GLP-1 candidate, orforglipron, and increasing prescription strength for its injectable drug tirzepatide suggest it is now pulling ahead in the booming market for incretin-based weight-loss treatments.
While Novo had the head start with semaglutide, BMO analysts believe the first-mover advantage has waned.
BMO says that Lilly’s growing edge in both clinical and commercial fronts is set to intensify with upcoming data from its ACHIEVE-1 trial in Type 2 diabetes.
Novo’s lack of a clear small-molecule strategy beyond peptides in the oral segment is likely to hamper its long-term growth, BMO added.
The firm also flagged continued fallout from last year’s supply disruptions of semaglutide, which may have pushed physicians to favor Lilly’s tirzepatide more permanently.
Novo’s next catalysts, including Alzheimer’s-related trials EVOKE and EVOKE+, could provide upside, but BMO described them as high risk and unlikely to shift sentiment meaningfully in the near term
The stock is down roughly 34% so far this year despite the soaring demand for its GLP-1-based therapies, Wegovy and Ozempic.
Related articles
Novo Nordisk downgraded by BMO as Eli Lilly gains ground in weight-loss drug race
TSX higher after BoC maintains key rate
RJ downgrades Coty; sees tepid earnings season for beauty and personal care sector
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。